Pasha Sarraf

CIK: 0002059447

Transaction Breakdown

Open Market Buys (P)5 (55.6%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (44.4%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

CUE

Cue Biopharma, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (9 total)

CUE
Cue Biopharma, Inc.
Jul 9, 2026
Award(A)
Direct
18.4K shares-
CUE
Cue Biopharma, Inc.
Jul 9, 2026
Award(A)
Direct
21.8K shares-
CUE
Cue Biopharma, Inc.
Jan 2, 2026
Award(A)
Stock Option (right to buy)
Direct
24.4K shares-
CUE
Cue Biopharma, Inc.
Dec 30, 2025
Purchase(P)
Direct
78.1K shares at avg. $0.31$24K
CUE
Cue Biopharma, Inc.
Dec 30, 2025
Purchase(P)
Direct
4.2K shares at avg. $0.31$1K
CUE
Cue Biopharma, Inc.
Dec 30, 2025
Purchase(P)
Direct
77.4K shares at avg. $0.30$23K
CUE
Cue Biopharma, Inc.
Dec 30, 2025
Purchase(P)
Direct
77.1K shares at avg. $0.30$23K
CUE
Cue Biopharma, Inc.
Dec 30, 2025
Purchase(P)
Direct
86.9K shares at avg. $0.32$28K
CUE
Cue Biopharma, Inc.
Mar 10, 2025
Award(A)
Stock Option (right to buy)
Direct
48.8K shares-

		Type	Shares	Price		Ownership
Jul 9, 2026	CUE Cue Biopharma, Inc.	Award(A)	18,400	-	$0	Direct
Jul 9, 2026	CUE Cue Biopharma, Inc.	Award(A)	21,800	-	$0	Direct
Jan 2, 2026	CUE Cue Biopharma, Inc.	Award(A) Stock Option (right to buy)	24,400	-	-	Direct
Dec 30, 2025	CUE Cue Biopharma, Inc.	Purchase(P)	78,116	$0.31	$24,325	Direct
Dec 30, 2025	CUE Cue Biopharma, Inc.	Purchase(P)	4,229	$0.31	$1,308	Direct
Dec 30, 2025	CUE Cue Biopharma, Inc.	Purchase(P)	77,417	$0.30	$23,349	Direct
Dec 30, 2025	CUE Cue Biopharma, Inc.	Purchase(P)	77,148	$0.30	$23,168	Direct
Dec 30, 2025	CUE Cue Biopharma, Inc.	Purchase(P)	86,947	$0.32	$27,597	Direct
Mar 10, 2025	CUE Cue Biopharma, Inc.	Award(A) Stock Option (right to buy)	48,800	-	-	Direct

1-9 of 9 transactions

About Sarraf Pasha

Sarraf Pasha (SEC CIK 0002059447) files insider reports with the SEC as Director of Cue Biopharma, Inc. (CUE).

Signal8 holds 6 ownership filings by Sarraf Pasha (1 Form 3, 5 Form 4), filed between Mar 12, 2025 and Aug 28, 2026. Those filings report 9 transactions, from Mar 10, 2025 to Jul 9, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Sarraf Pasha's filings is in BOSTON, MA.

Recent filings by Sarraf Pasha

Jul 9, 2026: Grants or awards of CUE shares (2 lines, Form 4, code A).
Jan 2, 2026: Grant or award of CUE derivative securities (Form 4, code A).
Dec 30, 2025: Open-market purchases of CUE shares (5 lines, Form 4, code P).
Mar 10, 2025: Grant or award of CUE derivative securities (Form 4, code A).

Other insiders filing for Cue Biopharma, Inc. (CUE)

Ray Sumita, Chief Legal Compliance Officer
Meluzio Michael Vincent, VP, Prin. Accounting Officer
Lin Shao-Lee, Chief Executive Officer
Garzone Pamela, Director
Ahlers James M, Chief Financial Officer
Borie Dominique Christian, Chief Medical Officer

How to read Form 4 transaction codes